Toutes les études
RecrutementPHASE3INTERVENTIONNEL

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

This research study is about a medicine called mezagitamab, which is being tested in adults who have a health problem called Immune Thrombocytopenic Purpura (ITP). ITP is a condition where your body’s defence system mistakenly harms your platelets, making it harder for your blood to clot. The main goal of this study is to see how safe mezagitamab is and if people can tolerate it well over a longer period. We also want to understand how effective it is and how your body uses the medicine. Only people who have already taken part in specific earlier mezagitamab studies (TAK-079-3002 or TAK-079-1004) will be invited to participate in this follow-up study.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
Takeda
Objectif d'inscription
150
Démarrer
14 août 2025
Achèvement estimé
29 Jul 2029

De quoi parle cette étude ?

This study is looking at a new medicine called mezagitamab for a condition known as Immune Thrombocytopenic Purpura, or ITP. If you have ITP, your body's immune system mistakenly attacks and destroys your platelets. Platelets are tiny cells in your blood that help it to clot and stop bleeding. When you have fewer platelets, you might bruise more easily or bleed for longer.

The main purpose of this study is to continue observing how safe mezagitamab is for people with ITP, and how well their bodies tolerate it when taken over a longer time. We also want to understand how effective the medicine is in managing ITP and how it works within the body.

This isn't a new study for everyone. It's a follow-up for people who have already taken part in two specific mezagitamab studies, called TAK-079-3002 or TAK-079-1004. If you were in those studies, you might be invited to join this one. You’ll only receive mezagitamab in this study if you meet specific requirements established before the study begins.

Points clés

  • This is a follow-up study for people previously in specific mezagitamab trials.
  • It aims to understand long-term safety and effectiveness of mezagitamab for ITP.
  • Participation involves regular clinic visits for health checks and blood tests.
  • You must be 18 years or older and meet specific health criteria to join.
  • La participation est volontaire, et vous pouvez vous retirer à tout moment.

Qui peut être éligible ?

To be able to join this study, you must have previously completed one of two specific mezagitamab studies: TAK-079-3002 or TAK-079-1004. If you were in the TAK-079-1004 study, you must have shown a positive response to mezagitamab during that study. You must also be 18 years old or older.

There are certain reasons why you might not be able to join. For example, if you have severe allergies to certain proteins or ingredients in the mezagitamab medicine. If you were part of the TAK-079-1004 study, you might not be eligible if you've had a blood clot or a stroke in the last year, or if you had your spleen removed in the last three months. You also can't have active hepatitis B or C, or HIV.

Other reasons that might prevent you from joining include a history of cancer in the last five years (except for certain skin cancers or cervical cancer), or if your doctor believes another serious health issue could affect your participation. If you've recently had certain treatments that affect your immune system, or are taking blood-thinning medicines, this might also mean you can't join.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. J'ai 18 ans ou plus.
  2. I have previously completed the TAK-079-3002 or TAK-079-1004 mezagitamab study.
  3. If I was in TAK-079-1004, I showed a positive response to mezagitamab during that study.
  4. I have not had a severe allergic reaction to mezagitamab or its ingredients.
  5. I have not had a blood clot or stroke in the last 12 months (if from TAK-079-1004).
  6. I do not have active hepatitis B or C, or HIV.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will continue to receive mezagitamab according to specific plans, as long as it's right for you. You will need to visit your study clinic several times during the course of the study. At these visits, the study team will carry out health checks, take blood samples, and ask about your health and how you are feeling. The study team will explain how often these visits will be. The total duration of your participation will depend on the study plan and your individual needs, but it is designed to follow your health over a longer period.

Risques et avantages potentiels

Taking part in any study has potential benefits and risks. A potential benefit of continuing in this study is that you may continue to receive mezagitamab, which could help manage your ITP. Researchers will also closely monitor your health. All medications have potential side effects, and mezagitamab is no different. The study team will explain any known side effects and what to look out for. You will be closely monitored for any health changes. Remember, joining this study is completely your choice, and you are free to stop participating at any time, for any reason, without it affecting your medical care.

Emplacements (118)

  • Genesis Cancer and Blood Institute - SCRI
    Code postal vérifié
    Hot Springs, United States· Pas encore en recrutement
  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC
    Code postal vérifié
    Los Angeles, États-Unis· Pas encore en recrutement
  • University of California San Diego Center for Bleeding and Clotting Disorders
    Code postal vérifié
    San Diego, États-Unis· Pas encore en recrutement
  • Rocky Mountain Cancer Center
    Code postal vérifié
    Denver, United States· Retiré
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
    Code postal vérifié
    Washington D.C., États-Unis· Pas encore en recrutement
  • Emory University
    Code postal vérifié
    Atlanta, États-Unis· Pas encore en recrutement
  • Innovative Hematology, Inc.
    Code postal vérifié
    Indianapolis, États-Unis· Pas encore en recrutement
  • The University of Iowa
    Code postal vérifié
    Iowa City, États-Unis· Pas encore en recrutement
  • University Of Louisville Brown Cancer Center
    Code postal vérifié
    Louisville, United States· Pas encore en recrutement
  • Hôpital Général du Massachusetts
    Code postal vérifié
    Boston, États-Unis· Recrutement
  • University of Massachusetts Chan Medical School
    Code postal vérifié
    Worcester, United States· Retiré
  • MidAmerica Cancer Center
    Code postal vérifié
    Kansas City, États-Unis· Pas encore en recrutement

Questions fréquentes

What is ITP?

ITP (Immune Thrombocytopenic Purpura) is a condition where your body's immune system mistakenly attacks and destroys your platelets, which are important for blood clotting.

What is mezagitamab?

Mezagitamab is the medicine being studied to see if it can help adults with ITP by managing their platelet levels.

Qui peut participer à cette étude ?

Only adults (18+) who have already participated in one of two specific mezagitamab studies (TAK-079-3002 or TAK-079-1004) can be invited to join this follow-up study.

What's the main goal of this study?

The main goal is to find out more about how safe mezagitamab is and how well people tolerate it over a longer time for managing ITP.

Devrai-je payer pour participer à l'étude ?

No, you will not have to pay to receive the study medication or for study-related visits and procedures.

Comment en savoir plus

Takeda Contact

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Follow-up Study of Mezagitamab in Adults With Chronic Prim… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.